|Bid||0.00 x 1000|
|Ask||0.00 x 1300|
|Day's Range||45.32 - 47.75|
|52 Week Range||30.02 - 58.72|
|Beta (5Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.33|
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks aren’t doing […]
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020.